Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Cytotherapy ; 25(5): 510-520, 2023 05.
Article in English | MEDLINE | ID: mdl-36882347

ABSTRACT

BACKGROUND AIMS: Third party virus-specific T cells (VST) has shown efficacy for opportunistic virus infection which do not have effective treatment or are drug-refractory. We describe our preparatory work in setting up a third-party VST bank for a multi-ethnic Asian population. METHODS: Discarded white cells from regular blood bank plateletpheresis donors with known locally prevalent HLA antigens were cultured in small scale to generate VST against Adenovirus, BK virus, Cytomegalovirus, Epstein-Barr virus, and Human Herpes Virus 6. Multi-virus specific T cells (multi-VST) were also generated against all 5 viruses in single cultures. A strategy of allelic typing for donors with good and broad-spectrum cytotoxicity together with consideration on HLA restriction for the virus epitope was used to select combinations of VST lines for a hypothetical third party VST bank. The breadth of coverage based on these selection criteria was validated using our database of 100 post haematopoietic stem cell transplant patients. RESULTS: We show that 50%, 42%, 56%, 56% and 42% of single VST cultures demonstrated specific cytotoxicity against AdV, BKV, CMV, EBV and HHV6 respectively. Twenty four of the 36 multi-VST lines showed activity against at least 2 of the 5 viruses studied. A carefully selected combination of just 6 VST lines can offer VST with at least 1 allelic match to 99% of potential recipients, while 92% can find 2 allelic matches and 79% can find 3 allelic matches. CONCLUSIONS: This preparatory work confirms that a cost-effective strategy recruiting a small number of pre-characterized donors can generate VST lines with broad coverage for a multi-ethnic Asian patient population, thereby laying the foundation for setting up of a third party VST bank for Asian patients.


Subject(s)
Epstein-Barr Virus Infections , Hematopoietic Stem Cell Transplantation , Humans , Cost-Benefit Analysis , Herpesvirus 4, Human , Immunotherapy, Adoptive , Adenoviridae , T-Lymphocytes
2.
J Endocrinol ; 247(1): 87, 2020 10.
Article in English | MEDLINE | ID: mdl-32755994

ABSTRACT

Toll-like receptors (TLRs), particularly TLR4, may act as immune sensors for metabolic stress signals such as lipids and link tissue metabolic changes to innate immunity. TLR signalling is not only tissue-dependent but also cell-type dependent and recent studies suggest that TLRs are not restricted to innate immune cells alone. Pancreatic islets, a hub of metabolic hormones and cytokines, respond to TLR signalling. However, the source of TLR signalling within the islet remain poorly understood. Uncovering the specific cell source and its role in mediating TLR signalling, especially within type 2 diabetes (T2D) islet will yield new targets to tackle islet inflammation, hormone secretion dysregulation and ultimately diabetes. In the present study, we immuno-characterised TLRs linked to pancreatic islets in both healthy and obese diabetic mice. We found that while TLRs1-4 and TLR9 were expressed in mouse islets, these TLRs did not co-localise with insulin-producing ß-cells. ß-Cells from obese diabetic mice were also devoid of these TLRs. While TLR immunoreactivity in obese mice islets increased, this was driven mostly by increased islet endothelial cell and islet macrophage presence. Analysis of human islet single-cell RNA-seq databases revealed that macrophages were an important source of islet TLRs. However, only TLR4 and TLR8 showed variation and cell-type specificity in their expression patterns. Cell depletion experiments in isolated mouse islets showed that TLR4 signalled through macrophages to alter islet cytokine secretome. Together, these studies suggest that islet macrophages are a dominant source of TLR4-mediated signalling in both healthy and diabetic islets.


Subject(s)
Cytokines/metabolism , Diabetes Mellitus, Type 2/metabolism , Islets of Langerhans/pathology , Macrophages/metabolism , Signal Transduction/physiology , Toll-Like Receptor 4/metabolism , Animals , Endothelial Cells/chemistry , Humans , Insulin-Secreting Cells/chemistry , Islets of Langerhans/chemistry , Macrophages/chemistry , Male , Mice , Obesity/metabolism , RNA, Messenger/analysis , Toll-Like Receptor 4/analysis , Toll-Like Receptor 4/genetics
3.
Am J Physiol Endocrinol Metab ; 317(6): E1108-E1120, 2019 12 01.
Article in English | MEDLINE | ID: mdl-31573842

ABSTRACT

ß-Cells respond to peripheral insulin resistance by first increasing circulating insulin during diabetes. Islet remodeling supports this compensation, but its drivers remain poorly understood. Infiltrating macrophages have been implicated in late-stage type 2 diabetes, but relatively little is known on islet resident macrophages, especially during compensatory hyperinsulinemia. We hypothesized that islet resident macrophages would contribute to islet vascular remodeling and hyperinsulinemia during diabetes, the failure of which results in a rapid progression to frank diabetes. We used chemical (clodronate), genetics (CD169-diphtheria toxin receptor mice), or antibody-mediated (colony-stimulating factor 1 receptor α) macrophage ablation methods in diabetic (db/db) and diet-induced models of compensatory hyperinsulinemia to investigate the role of macrophages in islet remodeling. We transplanted islets devoid of macrophages into naïve diabetic mice and assessed the impact on islet vascularization. With the use of the above methods, we showed that macrophage depletion significantly and consistently compromised islet remodeling in terms of size, vascular density, and insulin secretion capacity. Depletion of islet macrophages reduced VEGF-A secretion in both human and mouse islets ex vivo, and this functionally translated to delayed revascularization upon transplantation in vivo. We revealed that islet resident macrophages were associated with islet remodeling and increased insulin secretion during diabetes. This suggests utility in harnessing islet macrophages during this phase to promote islet vascularization, remodeling, and insulin secretion.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Hyperinsulinism/metabolism , Insulin Secretion , Insulin-Secreting Cells/metabolism , Islets of Langerhans/blood supply , Macrophages/physiology , Vascular Remodeling/physiology , Animals , Disease Models, Animal , Glucose/metabolism , Humans , Insulin-Secreting Cells/pathology , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , Islets of Langerhans Transplantation , Mice , Neovascularization, Physiologic , Organ Size , Vascular Endothelial Growth Factor A/metabolism
4.
Immunity ; 42(3): 484-98, 2015 Mar 17.
Article in English | MEDLINE | ID: mdl-25746953

ABSTRACT

Sepsis is characterized by a dysregulated inflammatory response to infection. Despite studies in mice, the cellular and molecular basis of human sepsis remains unclear and effective therapies are lacking. Blood monocytes serve as the first line of host defense and are equipped to recognize and respond to infection by triggering an immune-inflammatory response. However, the response of these cells in human sepsis and their contribution to sepsis pathogenesis is poorly understood. To investigate this, we performed a transcriptomic, functional, and mechanistic analysis of blood monocytes from patients during sepsis and after recovery. Our results revealed the functional plasticity of monocytes during human sepsis, wherein they transited from a pro-inflammatory to an immunosuppressive phenotype, while enhancing protective functions like phagocytosis, anti-microbial activity, and tissue remodeling. Mechanistically, hypoxia inducible factor-1α (HIF1α) mediated this functional re-programming of monocytes, revealing a potential mechanism for their therapeutic targeting to regulate human sepsis.


Subject(s)
Cellular Reprogramming/immunology , Hypoxia-Inducible Factor 1, alpha Subunit/immunology , Immunocompromised Host , Interleukin-1 Receptor-Associated Kinases/immunology , Sepsis/immunology , Adaptive Immunity , Convalescence , Cytokines/genetics , Cytokines/immunology , Gene Expression Profiling , Gene Expression Regulation , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Immunity, Innate , Interleukin-1 Receptor-Associated Kinases/genetics , Monocytes/immunology , Monocytes/pathology , Phagocytosis , Sepsis/genetics , Sepsis/pathology , Signal Transduction , Transcriptome/immunology
5.
Immunity ; 41(5): 815-29, 2014 Nov 20.
Article in English | MEDLINE | ID: mdl-25453823

ABSTRACT

Monocytes and macrophages are major components of the tumor microenvironment, but their contributions to human cancer are poorly understood. We used molecular profiling combined with functional assays to investigate the role of these cells in human renal cell carcinoma (RCC). Blood monocytes from RCC patients displayed a tumor-promoting transcriptional profile that supported functions like angiogenesis and invasion. Induction of this protumor phenotype required an interleukin-1 receptor (IL-1R)-dependent mechanism. Indeed, targeting of IL-1-IL-1R axis in a human RCC xenograft model abrogated the protumor phenotype of tumor-associated macrophages (TAMs) and reduced tumor growth in vivo. Supporting this, meta-analysis of gene expression from human RCC tumors showed IL1B expression to correlate with myelomonocytic markers, protumor genes, and tumor staging. Analyzing RCC patient tumors confirmed the protumor phenotype of TAMs. These data provide direct evidence for a tumor-promoting role of monocytes and macrophages in human cancer and indicate IL-1-IL-1R as a possible therapeutic target.


Subject(s)
Carcinoma, Renal Cell/immunology , Interleukin-1beta/immunology , Macrophages/immunology , Monocytes/immunology , Receptors, Interleukin-1/immunology , Animals , Cell Proliferation/genetics , Cytokines/biosynthesis , Cytokines/immunology , Gene Expression Profiling , Humans , Inflammation/immunology , Interleukin 1 Receptor Antagonist Protein/pharmacology , Interleukin-1beta/antagonists & inhibitors , Interleukin-1beta/biosynthesis , Interleukin-1beta/genetics , Mice , Mice, Knockout , Mice, SCID , Myeloid Differentiation Factor 88 , Neoplasm Transplantation , Neovascularization, Pathologic , Receptors, Interleukin-1/antagonists & inhibitors , Receptors, Interleukin-1/genetics , Transcription Factor RelA/genetics , Transplantation, Heterologous , Tumor Cells, Cultured
6.
Immunol Res ; 53(1-3): 11-24, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22418728

ABSTRACT

The role of myelomonocytic cells like monocytes and macrophages as first line of host defense is well established. Recent understanding of these cells using systems biology, transgenesis and in disease models has brought them to a center stage in orchestrating crucial functions during homeostasis and pathogenesis. Thus, understanding the functional diversity of these cells in health and disease as well as the mechanisms that control these events would be crucial for designing strategies for regulating disease and reinstate homeostasis.


Subject(s)
Macrophages/immunology , Metabolic Diseases/immunology , Neoplasms/immunology , Sepsis/immunology , Animals , Cell Differentiation , Health , Homeostasis , Humans , Immunity, Innate , Immunomodulation , Th1-Th2 Balance
7.
Blood ; 119(1): 227-37, 2012 Jan 05.
Article in English | MEDLINE | ID: mdl-22058116

ABSTRACT

Myelomonocytic cells play a key role in the progression of many solid tumors. However, very little is known about their contribution to the progression of hematopoietic cancers. We investigated the role of monocytes in the progression of human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We demonstrated that coculturing human monocytes in vitro with CD19+ BCP-ALL blasts from patients "conditioned" them to an inflammatory phenotype characterized by significant up-regulation of the chemokine, CXCL10. This phenotype was also observable ex vivo in monocytes isolated from BCP-ALL patients, which show elevated CXCL10 production compared with monocytes from healthy donors. Functionally, the "conditioned" monocytes promoted migration and invasive capacity of BCP-ALL cells. Increased invasion was mediated by matrix metalloproteinase 9 expression and activity in the BCP-ALL cells induced by the monocyte-derived CXCL10. However, neither the "conditioned" monocytes nor the CXCL10 produced by these cells had any effect on the proliferation/viability of BCP-ALL cells and angiogenesis. Collectively, our results strongly suggest a protumoral role for human monocytes in BCP-ALL, orchestrated by CXCL10 and its effect on tumor cell migration and invasion. These observations highlight the importance of the CXCL10/CXCR3 chemokine circuit in BCP-ALL progression.


Subject(s)
Cell Movement , Chemokine CXCL10/metabolism , Macrophages/pathology , Monocytes/pathology , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/etiology , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology , Adolescent , Blotting, Western , Cell Adhesion , Cell Proliferation , Child , Child, Preschool , Cytokines/metabolism , Female , Humans , Inflammation/etiology , Inflammation/metabolism , Inflammation/pathology , Macrophages/immunology , Macrophages/metabolism , Male , Matrix Metalloproteinase 9 , Monocytes/immunology , Monocytes/metabolism , Neoplasm Invasiveness , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Signal Transduction , Tumor Cells, Cultured
8.
Eur J Immunol ; 40(8): 2296-307, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20468007

ABSTRACT

Regulation of adaptive immunity by innate immune cells is widely accepted. Conversely, adaptive immune cells can also regulate cells of the innate immune system. Here, we report for the first time the essential role of B cells in regulating macrophage (Mφ) phenotype. In vitro B cell/Mφ co-culture experiments together with experiments in transgenic mice models for B-cell deficiency or overexpression showed B1 cells to polarize Mφ to a distinct phenotype. This was characterized by downregulated TNF-α, IL-1ß and CCL3, but upregulated IL-10 upon LPS stimulation; constitutive expression of M2 Mφ markers (e.g. Ym1, Fizz1) and overexpression of TRIF-dependent cytokines (IFN-ß, CCL5). Mechanistically, this phenotype was linked to a defective NF-κB activation, but a functional TRIF/STAT1 pathway. B1-cell-derived IL-10 was found to be instrumental in the polarization of these Mφ. Finally, in vivo relevance of B1-cell-induced Mφ polarization was confirmed using the B16 melanoma tumor model where adoptive transfer of B1 cells induced an M2 polarization of tumor-associated Mφ. Collectively, our results define a new mechanism of Mφ polarization wherein B1 cells play a key role in driving Mφ to a unique, but M2-biased phenotype. Future studies along these lines may lead to targeting of B1 cells to regulate Mφ response in inflammation and cancer.


Subject(s)
Antigens, Differentiation/metabolism , B-Lymphocytes/metabolism , Cell Differentiation , Cytokines/biosynthesis , Macrophages/metabolism , Adaptive Immunity , Adaptor Proteins, Vesicular Transport/metabolism , Adoptive Transfer , Animals , Antigens, Differentiation/genetics , B-Lymphocytes/immunology , B-Lymphocytes/pathology , B-Lymphocytes/transplantation , Cell Communication/immunology , Cell Differentiation/immunology , Coculture Techniques , Cytokines/genetics , Immunity, Innate , Macrophages/immunology , Macrophages/pathology , Melanoma, Experimental , Mice , Mice, Transgenic , NF-kappa B/metabolism , Transcriptional Activation
9.
Exp Cell Res ; 314(19): 3551-62, 2008 Nov 15.
Article in English | MEDLINE | ID: mdl-18835266

ABSTRACT

The SYT proto-oncoprotein (also known as SS18) is a gene expression regulator conserved across species. Although its biological function is still unknown, the importance of SYT as a housekeeping protein is illustrated by the lethal phenotype of SYT-null embryos. Notably, SYT is a component of the synovial sarcoma-associated translocation product, the SYT-SSX oncogene. SYT was previously reported as a mediator of cell adhesion. In the present study we show that SYT possesses distinct domains that control MDCK cyst formation in three-dimensional collagen cultures. While the carboxy-half of SYT, the QPGY domain, is required for cyst growth, the amino-terminal region appears to exert on this process a regulatory effect. Further analysis suggested that the purinergic G protein-coupled P2Y receptor signaling is involved in SYT-induced cystogenesis. Activation of this cascade is due to facilitation of ATP release in the extracellular space of polarized MDCK cells by SYT. These studies allow us to begin to understand the vital role of SYT in controlling epithelial morphogenesis and might explain the lethality of its loss in the developing embryo.


Subject(s)
Adenosine Triphosphate/metabolism , Epithelial Cells/cytology , Proto-Oncogene Proteins/metabolism , Animals , Cell Polarity , Cells, Cultured , Cysts/metabolism , Dogs , Epithelial Cells/metabolism , Extracellular Space/metabolism , Humans , Microscopy, Confocal , Models, Biological , Receptors, Purinergic P2/metabolism , Repressor Proteins/metabolism
10.
Cancer Res ; 68(16): 6822-30, 2008 Aug 15.
Article in English | MEDLINE | ID: mdl-18701508

ABSTRACT

Herein, using transgenic adenocarcinoma of the mouse prostate (TRAMP) model, we assessed the "stage-specific" efficacy of silibinin feeding against prostate cancer (PCa) initiation, progression, angiogenesis and metastasis, and associated molecular events involved in silibinin effects during these stages. Male TRAMP mice starting at ages 4, 12, 20, and 30 weeks of age were fed with control or 1% silibinin-supplemented diet for 8 to 15 weeks in stage-specific manners. At the end of studies, silibinin-fed mice showed less severe prostatic lesions compared with positive controls. During early stages of prostate tumor development, silibinin mediated its efficacy mostly via antiproliferative mechanisms. Feeding of silibinin to animals burdened with higher stages of prostate tumor significantly decreased tumor grade via antiproliferative effect, and inhibition of angiogenesis as evidenced by decreased expressions of platelet endothelial cell adhesion molecule-1/CD-31, vascular endothelial growth factor, and associated receptor, vascular endothelial growth factor R2, hypoxia-inducible factor-1alpha, and inducible nitric oxide synthase. Metastasis to distant organs was decreased in silibinin-fed mice, which was associated with a decreased expression of matrix metalloproteinases, mesenchymal markers snail-1, and fibronectin in the prostatic tissue and retention of epithelial characteristics. Together, these findings are both novel and highly significant in establishing the dual efficacy of silibinin where it inhibits progression of primary prostatic tumor and also shows protective efficacy against angiogenesis and late stage metastasis. These effects of silibinin could have potential implications to improve the morbidity and survival in PCa patients.


Subject(s)
Adenocarcinoma/prevention & control , Antioxidants/therapeutic use , Disease Models, Animal , Neovascularization, Pathologic/prevention & control , Prostatic Neoplasms/blood supply , Prostatic Neoplasms/prevention & control , Adenocarcinoma/blood supply , Adenocarcinoma/secondary , Animals , Apoptosis , Biomarkers, Tumor , Blotting, Western , Body Weight/drug effects , Cell Cycle Proteins/metabolism , Cell Movement , Cell Proliferation/drug effects , Disease Progression , Female , Humans , Immunoenzyme Techniques , Kidney Neoplasms/blood supply , Kidney Neoplasms/prevention & control , Kidney Neoplasms/secondary , Liver Neoplasms/blood supply , Liver Neoplasms/prevention & control , Liver Neoplasms/secondary , Lung Neoplasms/blood supply , Lung Neoplasms/prevention & control , Lung Neoplasms/secondary , Male , Mice , Mice, Inbred C57BL , Mice, Nude , Mice, Transgenic , Silybum marianum , Neoplasm Staging , Nitric Oxide Synthase Type II/metabolism , Prostate/drug effects , Prostatic Intraepithelial Neoplasia/blood supply , Prostatic Intraepithelial Neoplasia/prevention & control , Prostatic Intraepithelial Neoplasia/secondary , Prostatic Neoplasms/pathology , Silybin , Silymarin/therapeutic use , Tumor Cells, Cultured , Vascular Endothelial Growth Factor A/metabolism , Xenograft Model Antitumor Assays
11.
Mol Cancer Ther ; 7(7): 1817-26, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18644994

ABSTRACT

Recently, we reported that silibinin inhibits primary lung tumor growth and progression in mice and down-regulates inducible nitric oxide synthase (iNOS) expression in tumors; however, the mechanisms of silibinin action are largely not understood. Also, the activation of signaling pathways inducing various transcription factors are associated with lung carcinogenesis and their inhibition could be an effective strategy to prevent and/or treat lung cancer. Herein, we used human lung epithelial carcinoma A549 cells to explore the potential mechanisms and observed strong iNOS expression by cytokine mixture (containing 100 units/mL IFN-gamma + 0.5 ng/mL interleukin-1beta + 10 ng/mL tumor necrosis factor-alpha). We also examined the cytokine mixture-activated signaling cascades, which could potentially up-regulate iNOS expression, and then examined the effect of silibinin (50-200 mumol/L) on these signaling cascades. Silibinin treatment inhibited, albeit to different extent, the cytokine mixture-induced activation of signal transducer and activator of transcription 1 (Tyr(701)), signal transducer and activator of transcription 3 (Tyr(705)), activator protein-1 family of transcription factors, and nuclear factor-kappaB. The results for activator protein-1 were correlated with the decreased nuclear levels of phosphorylated c-Jun, c-Jun, JunB, JunD, phosphorylated c-Fos, and c-Fos. Further, silibinin also strongly decreased cytokine mixture-induced phosphorylation of extracellular signal-regulated kinase 1/2 but only marginally affected JNK1/2 phosphorylation. Silibinin treatment also decreased constitutive p38 phosphorylation in the presence or absence of cytokine mixture. Downstream of these pathways, silibinin strongly decreased cytokine mixture-induced expression of hypoxia-inducible factor-1alpha without any considerable effect on Akt activation. Cytokine mixture-induced iNOS expression was completely inhibited by silibinin. Overall, these results suggest that silibinin could target multiple cytokine-induced signaling pathways to down-regulate iNOS expression in lung cancer cells and that could contribute to its overall cancer preventive efficacy against lung tumorigenesis.


Subject(s)
Antineoplastic Agents/pharmacology , Cytokines/pharmacology , Down-Regulation/drug effects , Lung Neoplasms/enzymology , Nitric Oxide Synthase Type II/metabolism , Signal Transduction/drug effects , Cell Line, Tumor , Enzyme Activation/drug effects , Humans , Hypoxia-Inducible Factor 1, alpha Subunit , Mitogen-Activated Protein Kinases/metabolism , NF-kappa B/metabolism , Proto-Oncogene Proteins c-akt/metabolism , STAT1 Transcription Factor/metabolism , STAT3 Transcription Factor/metabolism , Silybin , Silymarin/pharmacology , Time Factors , Transcription Factor AP-1/metabolism
12.
J Natl Cancer Inst ; 98(12): 846-55, 2006 Jun 21.
Article in English | MEDLINE | ID: mdl-16788158

ABSTRACT

BACKGROUND: Silibinin, a flavanone from milk thistle, inhibits the growth of tumors in several rodent models. We examined the effects of dietary silibinin on the growth, progression, and angiogenesis of urethane-induced lung tumors in mice. METHODS: A/J mice (15 per group) were injected with urethane (1 mg/g body weight) or saline alone and fed normal diets for 2 weeks, after which they were fed diets containing different doses of silibinin (0%-1% [wt/wt] silibinin) for 18 or 27 weeks. Immunohistochemistry and Western blot analysis were used to examine angiogenesis and enzymatic markers of inflammation, proliferation, and apoptosis. All statistical tests were two-sided. RESULTS: Urethane-injected mice exposed to silibinin had statistically significantly lower lung tumor multiplicities than urethane-injected mice fed the control diet lacking silibinin (i.e., control mice). Mice that received urethane and 1% (wt/wt) dietary silibinin for 18 weeks had 93% fewer large (i.e., 1.5-2.5-mm-diameter) lung tumors than control mice (mean number of tumors/mouse: 27 in the urethane group versus 2 in the urethane + 1% silibinin group, difference = 25 tumors/mouse, 95% confidence interval [CI] = 13 to 37 tumors/mouse, P = .005). Lung tumors of silibinin-fed mice had 41%-74% fewer cells positive for the cell proliferation markers proliferating cell nuclear antigen and cyclin D1 than lung tumors of control mice. Tumor microvessel density was reduced by up to 89% with silibinin treatment (e.g., 56 microvessels/400x field in tumors from control mice versus 6 microvessels/400x field in tumors from urethane + 1% silibinin-treated mice [difference = 50 microvessels/400x field, 95% CI = 46 to 54 microvessels/400x field; P<.001]). Silibinin decreased lung tumor expression of vascular endothelial growth factor (VEGF) and of inducible nitric oxide synthase and cyclooxygenase-2, two enzymes that promote lung tumor growth and progression by inducing VEGF expression. CONCLUSIONS: Silibinin inhibits lung tumor angiogenesis in an animal model and merits investigation as a chemopreventive agent for suppressing lung cancer progression.


Subject(s)
Antineoplastic Agents/pharmacology , Biomarkers, Tumor/metabolism , Lung Neoplasms/drug therapy , Animals , Apoptosis/drug effects , Blotting, Western , Carcinogens , Cell Proliferation/drug effects , Cyclin D1/drug effects , Cyclooxygenase 2/drug effects , Disease Models, Animal , Fibroblast Growth Factor 2/drug effects , Immunohistochemistry , Inflammation/drug therapy , Lung Neoplasms/blood supply , Lung Neoplasms/chemically induced , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mice , Microcirculation/drug effects , Neovascularization, Pathologic/drug therapy , Nitric Oxide Synthase Type II/drug effects , Platelet Endothelial Cell Adhesion Molecule-1/drug effects , Proliferating Cell Nuclear Antigen/metabolism , Silybin , Silymarin/pharmacology , Urethane , Vascular Endothelial Growth Factor A/drug effects
13.
Tumori ; 92(2): 163-9, 2006.
Article in English | MEDLINE | ID: mdl-16724697

ABSTRACT

The radioprotective effects of naturally occurring sulfur compounds and isothiocyanates such as diallyl sulfide (DAS), diallyl disulfide (DADS), allyl methyl sulfide (AMS), allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) have been investigated in whole body irradiated Swiss albino mice. Administration of these sulfur compounds could reduce the serum content of alkaline phosphatase (ALP), which was elevated after irradiation (23.9 +/- 1.82 KA units). The elevated liver content of glutamate pyruvate transaminase (GPT) in control animals (76.2 +/- 2.2 U/mL) after irradiation was significantly reduced in DAS (58.93 +/- 4 U/mL) and AMS (55.7 +/- 2.2 U/mL) treated animals. Elevated levels of lipid peroxides in serum and liver of irradiated control animals were also significantly reduced by treatment with these sulfur compounds. The glutathione (GSH) content in liver and intestinal mucosa was drastically reduced after irradiation. All the sulfur compounds and isothiocyanates could effectively enhance the GSH content of intestinal mucosa and liver. Findings at histopathological analysis of the intestine proved to be correlated with the above results.


Subject(s)
Isothiocyanates/pharmacology , Radiation-Protective Agents/pharmacology , Sulfides/pharmacology , Allyl Compounds/pharmacology , Animals , Disulfides/pharmacology , Glutamate Synthase/metabolism , Glutathione/metabolism , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Lipid Peroxides/blood , Lipid Peroxides/metabolism , Liver/enzymology , Liver/metabolism , Mice , Pyruvate Synthase/metabolism , Thiocyanates/pharmacology , Transaminases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...